Search Results - "CECILE KREJSA" :: K.UTB vyhledávací portál | TBU Library Retrieval Portal

Antitumor Potency of an Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, Lisocabtagene Maraleucel in Combination With Ibrutinib or Acalabrutinib

Antitumor Potency of an Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, Lisocabtagene Maraleucel in Combination With Ibrutinib or Acalabrutinib

by Qin, Jim S, Johnstone, Timothy G, Baturevych, Alex, Hause, Ronald J, Ragan, Seamus P, Clouser, Christopher R, Jones, Jon C, Ponce, Rafael, Krejsa, Cecile M, Salmon, Ruth A, Ports, Michael O
Published in Journal of immunotherapy (1997) (01.05.2020)

Get more information

Journal Article

Bridging in vitro dissolution and in vivo exposure for acalabrutinib. Part II. A mechanistic PBPK model for IR formulation comparison, proton pump inhibitor drug interactions, and administration with acidic juices

Bridging in vitro dissolution and in vivo exposure for acalabrutinib. Part II. A mechanistic PBPK model for IR formulation comparison, proton pump inhibitor drug interactions, and administration with acidic juices

by Pepin, Xavier J.H., Moir, Andrea J., Mann, James C., Sanderson, Natalie J., Barker, Richard, Meehan, Elizabeth, Plumb, Allan P., Bailey, George R., Murphy, Dean S., Krejsa, Cecile M., Andrew, Marilee A., Ingallinera, Timothy G., Slatter, J. Greg
Published in European journal of pharmaceutics and biopharmaceutics (01.09.2019)

Get full text

Journal Article

Rapid Activation of Glutamate Cysteine Ligase following Oxidative Stress

Rapid Activation of Glutamate Cysteine Ligase following Oxidative Stress

by Krejsa, Cecile M., Franklin, Christopher C., White, Collin C., Ledbetter, Jeffrey A., Schieven, Gary L., Kavanagh, Terrance J.
Published in The Journal of biological chemistry (21.05.2010)

Get full text

Journal Article

S207: NAVTEMADLIN, AN ORAL MDM2 INHIBITOR, ELIMINATES MYELOPROLIFERATIVE NEOPLASM‐BLAST PHASE (MPN‐BP) INITIATING CELLS AND PROLONGS LEUKEMIA‐FREE SURVIVAL (LFS) IN AN MPN‐BP PDX MODEL

S207: NAVTEMADLIN, AN ORAL MDM2 INHIBITOR, ELIMINATES MYELOPROLIFERATIVE NEOPLASM‐BLAST PHASE (MPN‐BP) INITIATING CELLS AND PROLONGS LEUKEMIA‐FREE SURVIVAL (LFS) IN AN MPN‐BP PDX MODEL

by Wang, Xiaoli, Hu, Cing Siang, Davis, Andrew, Krejsa, Cecile, Hoffman, Ronald
Published in HemaSphere (08.08.2023)

Get full text

Journal Article

PB2205: A MECHANISTIC ABSORPTION AND PHARMACOKINETIC MODEL OF COVALENT BTK INHIBITOR TL‐895: INFLUENCE OF FOOD AND ACID REDUCING AGENTS

PB2205: A MECHANISTIC ABSORPTION AND PHARMACOKINETIC MODEL OF COVALENT BTK INHIBITOR TL‐895: INFLUENCE OF FOOD AND ACID REDUCING AGENTS

by Macwan, Joyce, Fraczkiewicz, Grace, Podoll, Terry, Allard, Martine, Krejsa, Cecile, Slatter, Greg
Published in HemaSphere (08.08.2023)

Get full text

Journal Article

Preclinical Evaluation of the Novel BTK Inhibitor Acalabrutinib in Canine Models of B-Cell Non-Hodgkin Lymphoma

Preclinical Evaluation of the Novel BTK Inhibitor Acalabrutinib in Canine Models of B-Cell Non-Hodgkin Lymphoma

by Harrington, Bonnie K, Gardner, Heather L, Izumi, Raquel, Hamdy, Ahmed, Rothbaum, Wayne, Coombes, Kevin R, Covey, Todd, Kaptein, Allard, Gulrajani, Michael, Van Lith, Bart, Krejsa, Cecile, Coss, Christopher C, Russell, Duncan S, Zhang, Xiaoli, Urie, Bridget K, London, Cheryl A, Byrd, John C, Johnson, Amy J, Kisseberth, William C
Published in PloS one (19.07.2016)

Get full text

Journal Article

Protein therapeutics: new applications for pharmacogenetics

Protein therapeutics: new applications for pharmacogenetics

by Krejsa, Cecile, Rogge, Mark, Sadee, Wolfgang
Published in Nature reviews. Drug discovery (01.06.2006)

Get full text

Journal Article

Fluorescence-based microtiter plate assay for glutamate–cysteine ligase activity

Fluorescence-based microtiter plate assay for glutamate–cysteine ligase activity

by White, Collin C, Viernes, Hannah, Krejsa, Cecile M, Botta, Dianne, Kavanagh, Terrance J
Published in Analytical biochemistry (15.07.2003)

Get full text

Journal Article

B-lymphocyte stimulator/a proliferation-inducing ligand heterotrimers are elevated in the sera of patients with autoimmune disease and are neutralized by atacicept and B-cell maturation antigen-immunoglobulin

B-lymphocyte stimulator/a proliferation-inducing ligand heterotrimers are elevated in the sera of patients with autoimmune disease and are neutralized by atacicept and B-cell maturation antigen-immunoglobulin

by Dillon, Stacey R, Harder, Brandon, Lewis, Kenneth B, Moore, Margaret D, Liu, Hong, Bukowski, Thomas R, Hamacher, Nels B, Lantry, Megan M, Maurer, Mark, Krejsa, Cecile M, Ellsworth, Jeff L, Pederson, Susan, Elkon, Keith B, Wener, Mark H, Dall'Era, Maria, Gross, Jane A
Published in Arthritis research & therapy (01.01.2010)

Get full text

Journal Article

P991: ADDING NAVTEMADLIN (NVTM) TO RUXOLITINIB (RUX) POTENTIATES APOPTOSIS IN MYELOBLASTS FROM PATIENTS (PTS) WITH MYELOFIBROSIS (MF)

P991: ADDING NAVTEMADLIN (NVTM) TO RUXOLITINIB (RUX) POTENTIATES APOPTOSIS IN MYELOBLASTS FROM PATIENTS (PTS) WITH MYELOFIBROSIS (MF)

by Clevenger, Tracy, Cheung, Jean, Krantz, Fanny, Gulrajani, Michael, Nguyen, Cynthia, Luarca, Miranda, Krejsa, Cecile, Rothbaum, Wayne P., Covey, Todd
Published in HemaSphere (08.08.2023)

Get full text

Journal Article

P1006: CHARACTERIZATION OF TL‐895: A NOVEL BRUTON TYROSINE KINASE INHIBITOR (BTKI) IN CLINICAL DEVELOPMENT FOR CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) AND MYELOFIBROSIS (MF)

P1006: CHARACTERIZATION OF TL‐895: A NOVEL BRUTON TYROSINE KINASE INHIBITOR (BTKI) IN CLINICAL DEVELOPMENT FOR CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) AND MYELOFIBROSIS (MF)

by Gulrajani, Michael, Clevenger, Tracy, Cheung, Jean, Krantz, Fanny, Nguyen, Cynthia, Luarca, Miranda, Krejsa, Cecile, Rothbaum, Wayne P., Covey, Todd
Published in HemaSphere (08.08.2023)

Get full text

Journal Article

Interleukin-21 enhances rituximab activity in a cynomolgus monkey model of B cell depletion and in mouse B cell lymphoma models

Interleukin-21 enhances rituximab activity in a cynomolgus monkey model of B cell depletion and in mouse B cell lymphoma models

by Krejsa, Cecile M, Holly, Rick D, Heipel, Mark, Bannink, Ken M, Johnson, Rebecca, Roque, Richard, Heffernan, Jane, Hill, Julie, Chin, Lay, Wagener, Felecia, Shiota, Faith, Henderson, Katherine, Sivakumar, Pallavur V, Ren, Hong-Ping, Barahmand-Pour, Fariba, Foster, Don, Clegg, Chris, Kindsvogel, Wayne, Ponce, Rafael, Hughes, Steven D, Waggie, Kim
Published in PloS one (25.06.2013)

Get full text

Journal Article

P1005: EFFECT OF TL‐895, A NOVEL BRUTON’S TYROSINE KINASE INHIBITOR (BTKI), ON ONCOGENIC JANUS KINASE 2‐V617F (JAK2VF) SIGNALING

P1005: EFFECT OF TL‐895, A NOVEL BRUTON’S TYROSINE KINASE INHIBITOR (BTKI), ON ONCOGENIC JANUS KINASE 2‐V617F (JAK2VF) SIGNALING

by Chary Nimmagadda, Subbaiah, Marie Budde, Paulina, Sun, Kaiyan, Covey, Todd, Krejsa, Cecile, Rothbaum, Wayne P., Bubnoff, Nikolas, Khandanpour, Cyrus
Published in HemaSphere (08.08.2023)

Get full text

Journal Article

PB2200: FOOD AND ACID REDUCING AGENT EFFECTS ON PHARMACOKINETICS (PK) AND PHARMACODYNAMICS (PD) OF THE COVALENT BRUTON TYROSINE KINASE INHIBITOR (BTKI) TL-895 IN HEALTHY SUBJECTS

PB2200: FOOD AND ACID REDUCING AGENT EFFECTS ON PHARMACOKINETICS (PK) AND PHARMACODYNAMICS (PD) OF THE COVALENT BRUTON TYROSINE KINASE INHIBITOR (BTKI) TL-895 IN HEALTHY SUBJECTS

by Allard, Martine, Krejsa, Cecile, Williams, Isaiah, Podoll, Terry, Steinmann, Kim, Slatter, Greg
Published in HemaSphere (08.08.2023)

Get full text

Journal Article

An inter-laboratory retrospective analysis of immunotoxicological endpoints in non-human primates: Flow cytometry immunophenotyping

An inter-laboratory retrospective analysis of immunotoxicological endpoints in non-human primates: Flow cytometry immunophenotyping

by Krejsa, Cecile M., Neradilek, Moni Blazej, Polissar, Nayak L., Cox, Nick, Clark, Darcey, Cowan, Laine, Bussiere, Jeanine, Lebrec, Herve
Published in Journal of immunotoxicology (01.10.2013)

Get full text

Journal Article

S214: DISEASE-MODIFYING ACTIVITY OF NAVTEMADLIN (NVTM) CORRELATED WITH SURVIVAL OUTCOMES IN JANUS KINASE INHIBITOR (JAKI) RELAPSED OR REFRACTORY (R/R) MYELOFIBROSIS (MF) PATIENTS (PTS)

S214: DISEASE-MODIFYING ACTIVITY OF NAVTEMADLIN (NVTM) CORRELATED WITH SURVIVAL OUTCOMES IN JANUS KINASE INHIBITOR (JAKI) RELAPSED OR REFRACTORY (R/R) MYELOFIBROSIS (MF) PATIENTS (PTS)

by Vachhani, Pankit, Perkins, Andrew, Mascarenhas, John, Al-Ali, Haifa Kathrin, Kiladjian, Jean-Jacques, Cerquozzi, Sonia, Dybko, Jaroslaw, Delgado, Regina Garcia, Rivas, Jesus Hernández, Hebart, Holger, Huang, Zhuying, Krejsa, Cecile, Qamoos, Hope, Mcgreivy, Jesse, Rothbaum, Wayne P., Verstovsek, Srdan, Vannucchi, Alessandro
Published in HemaSphere (08.08.2023)

Get full text

Journal Article

Glutamate-cysteine ligase attenuates TNF-induced mitochondrial injury and apoptosis

Glutamate-cysteine ligase attenuates TNF-induced mitochondrial injury and apoptosis

by Botta, Dianne, Franklin, Christopher C., White, Collin C., Krejsa, Cecile M., Dabrowski, Michael J., Pierce, Robert H., Fausto, Nelson, Kavanagh, Terrance J.
Published in Free radical biology & medicine (01.09.2004)

Get full text

Journal Article

TL-895, a Highly Selective, Covalent Inhibitor of Bruton's Tyrosine Kinase (BTK), Sensitizes Myeloproliferative Neoplasm (MPN)-Blast Phase Stem Cells to Navtemadlin By Targeting Intrinsic Dysregulated MDM2/p53 and NF-Κb Pathways and Disrupting the Protective Tumor Microenvironment (TME)

TL-895, a Highly Selective, Covalent Inhibitor of Bruton's Tyrosine Kinase (BTK), Sensitizes Myeloproliferative Neoplasm (MPN)-Blast Phase Stem Cells to Navtemadlin By Targeting Intrinsic Dysregulated MDM2/p53 and NF-Κb Pathways and Disrupting the Protective Tumor Microenvironment (TME)

by Wang, Xiaoli, Davis, Andrew, Su, Xiaoping, Muftuoglu, Muharrem, Krejsa, Cecile, Mascarenhas, John, Andreeff, Michael, Hoffman, Ronald
Published in Blood (02.11.2023)

Get full text

Journal Article

$Population Pharmacokinetic and Pharmacodynamic Analysis of Navtemadlin in Patients with Relapsed and Refractory (R/R) Myelofibrosis (MF) and Other Myeloid or Solid Tumor Malignancies$

Population Pharmacokinetic and Pharmacodynamic Analysis of Navtemadlin in Patients with Relapsed and Refractory (R/R) Myelofibrosis (MF) and Other Myeloid or Solid Tumor Malignancies

by Zhang, Lu, Poland, Bill, Xu, Shuang, Allard, Martine, Krejsa, Cecile, Slatter, J. Greg
Published in Blood (02.11.2023)

Get full text

Journal Article

Induction of glutamate-cysteine ligase (γ-glutamylcysteine synthetase) in the brains of adult female mice subchronically exposed to methylmercury

Induction of glutamate-cysteine ligase (γ-glutamylcysteine synthetase) in the brains of adult female mice subchronically exposed to methylmercury

by Thompson, Sally A, White, Collin C, Krejsa, Cecile M, Diaz, Dolores, Woods, James S, Eaton, David L, Kavanagh, Terrance J
Published in Toxicology letters (29.10.1999)

Get full text

Journal Article

1
2
3
4
5
6
7
8
9
10
Next
[10]